Agile therapeutics (AGRX) has had a, shall we say, crazy week in the market. On Monday, October 28, its share price was sent on a downward spiral following the release of negative briefing documents ...
Agile Therapeutics (NASDAQ:AGRX) just reported results for the fourth quarter of 2023. Agile Therapeutics reported earnings per share of -$1.46. This was below the analyst estimate for EPS of -92 ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Agile Therapeutics, Inc. (OTCQB: AGRX) to Insud Pharma, S.L. for $1.52 per share in cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results